Yakult Seeks Additional Indication For Colon Cancer Drug Elplat
This article was originally published in PharmAsia News
Executive Summary
Yakult Honsha applied for an additional indication with Japan's Ministry of Health, Labor and Welfare for Elplat (exaliplatin), a drug approved to treat progressive, recurring colon cancers and colon cancers that cannot be eliminated by surgery. The additional indication is to use the drug as a supplement to chemotherapy after colon cancer surgery. With the July 2009 expiration of patent protection for its major cancer drugCampto (irinotecan), Yakult aims to increase Elplat's target patients and expand the market to increase sales. (Click here for more - Japanese language) "Yakult Applies For Additional Indications For Cancer Drug" - Nikkei Sangyo News (9/2/08)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.